PepGen appoints Howard Mayer, M.D. to board of directors

PepGen Inc.

Howard Mayer appointed to PepGen board effective Nov 15, 2023; fills newly created vacancy expanding board to seven members.
Dr. Mayer will receive initial option for 22,686 shares under 2022 Stock Plan; annual cash retainers $35k for board, $5k for compensation committee.
Dr. Mayer was most recently EVP, Head of R&D at Ipsen Biopharmaceuticals (2019-2023); previously SVP, CMO at Shire Pharmaceuticals.
He brings experience in rare disease clinical development and regulatory filings; will serve on Compensation Committee.
No family relationships or arrangements with other persons regarding his appointment.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Howard Mayer

Director

PEPG · PepGen Inc.

Effective: 2023-11-10
Filed: November 15, 2023, 6:59 PM ET

On November 10, 2023, the Board of Directors (the “Board”) of PepGen Inc. (“PepGen”) on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Howard Mayer to fill a newly created vacancy on the Board resulting from the expansion of the number of members of the Board from six to seven.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Howard Mayer was appointed as Director at PepGen Inc..

Action: appointed
Role: Director

Exact text from the filing

On November 10, 2023, the Board of Directors (the “Board”) of PepGen Inc. (“PepGen”) on the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously appointed Howard Mayer to fill a newly created vacancy on the Board resulting from the expansion of the number of members of the Board from six to seven.

View on SEC.gov

PepGen Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-064008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.